You are here

Clinical Trials: Cord Blood

Conditions:   Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Deficiency Syndromes;   Langerhans-Cell Histiocytosis
Interventions:   Procedure: Stem Cell Transplant;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Anti-thymocyte globulin (ATG);   Drug: Campath 1H;   Drug: Cyclosporin A;   Drug: Mycophenolate mofetil;   Drug: Intravenous immunoglobulin (IVIG)
Sponsor:   Masonic Cancer Center, University of Minnesota
Completed
Conditions:   Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Diseases;   Langerhans-Cell Histiocytosis;   Hematologic Diseases
Interventions:   Procedure: Stem Cell Transplant;   Drug: Myeloablative conditioning regimen
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated
Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified July 2017
Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsor:   Roswell Park Cancer Institute
Active, not recruiting - verified March 2017
Condition:   Severe Combined Immunodeficiency Syndrome
Intervention:   Drug: CD34+ cells transduced with ADA retrovir
Sponsor:   National Human Genome Research Institute (NHGRI)
Completed - verified September 17, 2014
Conditions:   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methylprednisolone;   Procedure: bone marrow ablation with stem cell support;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsor:   Roswell Park Cancer Institute
Active, not recruiting - verified March 2017

Pages